


Journal Pre-proof

Azathioprine for the treatment of chronic spontaneous urticaria refractory to antihistamines, omalizumab, and ciclosporin: a case series

L. Mateu-Arrom R. Martín V. Expósito-Serrano A. Álvarez-Abella E.
Serra-Baldrich J. Spertino



PII: S0001-7310(25)00276-5

DOI: <https://doi.org/doi:10.1016/j.ad.2024.12.023>

Reference: AD 4350

To appear in: *Actas dermosifiliograficas*

Received Date: 7 August 2024

Accepted Date: 1 December 2024

Please cite this article as: Mateu-Arrom L, Martín R, Expósito-Serrano V, Álvarez-Abella A, Serra-Baldrich E, Spertino J, Azathioprine for the treatment of chronic spontaneous urticaria refractory to antihistamines, omalizumab, and ciclosporin: a case series, *Actas dermosifiliograficas* (2025), doi: <https://doi.org/10.1016/j.ad.2024.12.023>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier España, S.L.U. on behalf of AEDV.

Sección: Cartas científico clínicas

Azathioprine for the treatment of chronic spontaneous urticaria refractory to antihistamines, omalizumab, and ciclosporin: a case series

Azatioprina en el tratamiento de la urticaria crónica espontánea refractaria a antihistamínicos, omalizumab y ciclosporina: una serie de casos

Authors: L. Mateu-Arrom¹, R. Martín¹, V. Expósito-Serrano², A. Álvarez-Abella³, E. Serra-Baldrich¹, and J. Spertino¹

1. Dermatology Department, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Universitat Autònoma de Barcelona, Campus Salut Barcelona, Barcelona, Spain
2. Dermatology Department, Hospital Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Spain
3. Dermatology Department, Hospital Universitari MútuaTerrassa, Barcelona, Spain

Corresponding author:

Laura Mateu-Arrom

E-mail address: lmateuarrom@hotmail.com

To the Editor,

Chronic spontaneous urticaria (CSU) is defined by the appearance of a > 6-week history of wheals and/or angioedema without an identifiable triggering agent and significantly impacting the patients' quality of life¹.

Omalizumab is associated with high efficacy in the treatment of CSU¹. Furthermore, dose escalation, as recommended by clinical practice guidelines, can benefit most patients who exhibit a lack of response or partial response. On the other hand, treatment with ciclosporin (CsA)—recommended as a third-line therapy—has also been associated with high response rates, particularly in cases of type IIb autoimmunity². Therefore, non-responders to both omalizumab and CsA represent a small percentage of challenging-to-treat patients. However, there are no specific recommendations for further treatments in these patients, as alternative treatment options have limited low-quality evidence¹.

We report our experience with 7 cases of CSU refractory to antihistamines, omalizumab and CsA treated with azathioprine across 3 dermatology departments of tertiary referral centers. The cohort included a total of 5 women and 2 men, with a median age of 69 years (range, 17-85). Two patients (29%) exhibited concurrent chronic inducible urticaria (symptomatic dermographism and delayed pressure urticaria) and 5 (71%), angioedema. Additionally, 2 patients (29%) exhibited autoimmune thyroid disease, and 1 patient (14%), type 1 diabetes mellitus. Baseline blood test revealed the presence of anti-thyroid peroxidase antibodies in 3 patients, while median basal values of immunoglobulin E and D-dimer were 45 kU/L (2-1043) and 485 ng/mL (170-766), respectively. The median time of omalizumab and CsA treatment prior to azathioprine initiation were 11 (3-43) and 23 months (4-31), respectively.

The median dose of azathioprine was 1.2 mg/kg/day (0.5-2.3). Omalizumab was maintained in 4 (57%) patients while on azathioprine. Median values of the Urticaria Activity Score 7 (UAS7) and Urticaria Control Test (UCT) questionnaires—available for 6 out of 7 patients—are shown in Table 1.

A complete response (UAS7 = 0 and UCT = 16) was achieved in 4 (57%) patients after 3.2 months (1-7.2), 2 of them along with omalizumab. Two of these patients are still on azathioprine, and the remaining 2 discontinued treatment due to symptom resolution

with no relapse after discontinuation and no need for further treatment. The remaining 3 patients showed no response, one of them receiving a reduced dose of azathioprine of 0.5 mg/kg/day due to a thiopurine methyltransferase activity of 11.6 U/mL. Another non-responsive patient received the treatment for only 1.8 months due to hepatotoxicity, which resolved after treatment discontinuation. Two out of the 3 patients who remained unresponsive to azathioprine had an inducible urticaria.

Although failed omalizumab + CsA therapy is a rare finding, some patients still require further therapeutic options. Furthermore, CsA is not recommended for long-term use due to the high risk of renal damage². Azathioprine—a purine synthesis inhibitor—induces apoptosis of T lymphocytes³. Azathioprine has proven effective in CSU cases refractory to antihistamines^{4,5} or CsA³. In cases refractory to antihistamines, treatment with azathioprine has proven non-inferior to CsA, with similar outcomes achieved at 2 months and maximum response observed around 3 months of treatment⁵ as seen in patients included in our study. The non-responsive case observed in our series could be attributed to insufficient dosing due to TPMT activity in one patient, or limited treatment duration because of adverse event in another.

To this date, no cases of azathioprine after omalizumab and CsA treatment have been reported. Based on our results, azathioprine could represent an option for these very difficult-to-treat cases of CSU. While azathioprine was generally well tolerated, one case of hepatitis was identified, highlighting the necessity for close monitoring during treatment.

Ethics Statement: The patients in this manuscript have given written informed consent to publication of their case details.

Data availability statement: The data underlying this article will be shared on reasonable request to the corresponding author.

Funding sources: None

Conflicts of interest:

LMA and RM declared no conflicts of interest whatsoever. VES has been medical advisor and speaker for Abbvie, Lilly, LEO Pharma, Novartis, Amgen and Sanofi Genzyme. AAA declared to have received speaker fees by Novartis. ES declared to have received honoraria for speaking engagements, for his involvement in advisory boards, and advisory roles for the following pharmaceutical companies: Lilly, Amgen, Leo Pharma, Novartis, Pfizer, Sanofi, AbbVie, and Pierre Fabre. JS declared to have received speaker fees. Moreover, the has been involved in clinical trials sponsored by Abbvie, Lilly, LEO Pharma, Novartis and Sanofi Genzyme.

Declaración de autoría:

LMA and JS designed the work. LMA, RM, VES and AAA collected the data. LMA and JS drafted the manuscript. All authors revised the manuscript and approved the final version of the manuscript.

Ética de la publicación

1. ¿Su trabajo ha comportado experimentación en animales?:

No

2. ¿En su trabajo intervienen pacientes o sujetos humanos?:

Sí

Si la respuesta es afirmativa, por favor, mencione el comité ético que aprobó la investigación y el número de registro.:

Data were retrieved from the medical records and from a prospective registry started in 2009, which received the approval of our local Ethics Committee (16/049 (OBS)), enrolling patients with CSU.

Si la respuesta es afirmativa, por favor, confirme que los autores han cumplido las normas éticas relevantes para la publicación. :

Sí

Si la respuesta es afirmativa, por favor, confirme que los autores cuentan con el consentimiento informado de los pacientes. :

Sí

3. ¿Su trabajo incluye un ensayo clínico?:

No

4. ¿Todos los datos mostrados en las figuras y tablas incluidas en el manuscrito se recogen en el apartado de resultados y las conclusiones?:

Sí

References

1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy* [Internet]. 2022 Mar 1 [cited 2024 Mar 16];77(3):734–66. Available at: <https://pubmed.ncbi.nlm.nih.gov/34536239/>
2. Kulthanan K, Chaweeikulrat P, Komoltri C, Hunnangkul S, Tuchinda P, Chularojanamontri L, et al. Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review. *J Allergy Clin Immunol Pract* [Internet]. 2018 Mar 1 [cited 2024 Mar 2];6(2):586–99. Available at: <https://pubmed.ncbi.nlm.nih.gov/28916431/>
3. Tal Y, Toker O, Agmon-Levin N, Shalit M. Azathioprine as a therapeutic alternative for refractory chronic urticaria. *Int J Dermatol* [Internet]. 2015 Mar 1 [cited 2024 May 13];54(3):367–9. Available at: <https://pubmed.ncbi.nlm.nih.gov/25069708/>
4. Bhanja D, Ghoshal L, Das S, Das S, Roy A. Azathioprine in autologous serum skin test positive chronic urticaria: A case-control study in a tertiary care hospital of eastern India. *Indian Dermatol Online J* [Internet]. 2015 [cited 2024 May 13];6(3):185. Available at: <https://pubmed.ncbi.nlm.nih.gov/26009713/>
5. Pathania YS, Bishnoi A, Parsad D, Kumar A, Kumaran MS. Comparing azathioprine with cyclosporine in the treatment of antihistamine refractory chronic spontaneous urticaria: A randomized prospective active-controlled non-inferiority study. *World Allergy Organ J* [Internet]. 2019 Jan 1 [cited 2024 May 13];12(5). Available at: <https://pubmed.ncbi.nlm.nih.gov/31193160/>

Table 1. Results of UAS7 and UCT questionnaires prior, at the first control (after a median of 2 (1-4.2) months after starting azathioprine), and at the end of azathioprine therapy (after 10 (1.8-11) months of therapy).

	Baseline	At first clinical control	At the end of Aza treatment
UAS7 median (range) n = 6	24 (10-36)	8 (0-36)	0 (0-24)
UCT median (range) n = 6	5 (0-10)	11 (2-16)	16 (7-16)

UAS7: Urticaria Activity Score 7; UCT: Urticaria Control Test. Aza: Azathioprine.